Quarterly report pursuant to Section 13 or 15(d)

4. Significant Strategic Collaborations (Details Narrative)

v3.21.1
4. Significant Strategic Collaborations (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Revenue $ 191,216 $ 56,749  
Research and development expenses 629,729 359,651  
Prepaid expenses and other current asset 1,027,749   $ 841,958
Pharmsynthez [Member] | Sponsored Research Agreement [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Research and development expenses 100,000    
Prepaid expenses and other current asset 200,000   $ 200,000
Takeda [Member] | Royalty [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Revenue 200,000 100,000  
Serum Institute [Member] | Royalty [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Revenue 0 0  
SynBio [Member] | Royalty [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Revenue 0 $ 0  
Scripps [Member]      
Research and Development Arrangement, Contract to Perform for Others [Line Items]      
Research and development expenses $ 1,200,000